New Drug Innovation And Production Program To Focus On Ten Diseases
This article was originally published in PharmAsia News
Executive SummaryAt the 2009 International Conference for Bioeconomy in Tianjin, Sang Guowei, chief technology director for China's new drug innovation and production program, talked about progress in the program. Three objectives have been set: (1) developing new drugs with effectiveness, safety and low price; (2) cultivating specialized talent in the Yangtze River Delta, Pearl River Delta and Bohai Bay Rim to set up a healthcare system which conforms to China's conditions; and (3) speeding up TCM modernization. To meet the healthcare reform requirements, especially to align with those of rural medical cooperatives, the project will allocate 43 percent of its total research funds to fight 10 major diseases, including malignant tumors, cerebral and cardiac vascular diseases, diabetes, mental disorders, immunological diseases, AIDS, drug-resistant tuberculosis, drug-resistant tumors and viral diseases. (Click here for more - Chinese Language)
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.